The global ovarian cancer therapeutics market size was estimated at USD 1.2 billion in 2018 and is expected to grow at a CAGR of 6.2% during the forecast period. The rising prevalence of ovarian cancer and increasing emphasis on early diagnosis & treatment are expected to drive market growth. As of 2018, ovarian cancer had the highest mortality rate of all gynecologic cancers. It accounted for nearly 14,000 deaths in the U.S. in 2018. The disease has generic symptoms, such as bloating, abnormal menstruation, vaginal bleeding, indigestion, and fatigue, among others. No specific symptoms make an early diagnosis of the disease increasingly difficult.